Astrin Biosciences Forms Scientific Advisory Board to Advance AI-Driven Proteomics for Early Cancer Detection

Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.

Interest in proteomic diagnostics has accelerated as researchers look beyond genomics for earlier and more accurate detection tools. For health systems seeking noninvasive screening options, platforms that leverage AI to interpret complex protein data could offer a complementary route to earlier detection and improved outcomes.

Posted by MedCloudInsider Editors on 12/08/2025